EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients

Annette K Regan iD, Stacey L Rowe iD, Sheena G Sullivan, Matthew M Coates iD, Flor M Muñoz, Onyebuchi A Arah iD

Clinical Infectious Diseases · 17.03.2025 · 80 (3) · 512-519

DOI: 10.1093/cid/ciae580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.02.2025. Verfasst von Annette K Regan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena California, USA. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Pregnancy Complications, Infectious, COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pregnant people are at risk of severe coronavirus disease 2019 (COVID-19) and associated complications. While withholding treatment from pregnant patients is not recommended, little is known about the frequency of antiviral medication use during pregnancy.

Methods

Using Medicaid and commercial insurance databases, we constructed a national claims-based cohort study of pregnant, recently pregnant, and nonpregnant female patients 18–49 years old with an outpatient diagnosis of COVID-19 between 21 December 2021 and 30 September 2022. Outpatient treatment with a recommended antiviral medication was identified within 5 days of diagnosis, using national drug codes in outpatient prescription drug claims. Propensity score–matched prevalence ratios (PRs) were used to compare antiviral treatment by pregnancy status.

Results

A total of 412 755 publicly and privately insured patients with COVID-19 were identified, including 33 855 currently pregnant, 2460 recently pregnant, and 376 440 nonpregnant female patients; 6.8% had a record of antiviral medication use, including 1.3% of pregnant, 5.4% of recently pregnant, and 7.3% of nonpregnant women. Most commonly ritonavir-boosted nirmatrelvir was administered. The prevalence of antiviral medication use was 67% lower among pregnant patients compared with nonpregnant patients (PR, 0.33 [95% confidence interval, .30–.36]), even among patients with ≥1 high-risk medical condition (0.29 [.25–.33]). Antiviral medication use was slightly lower among recently pregnant women with ≥1 high-risk medical condition than among nonpregnant women with similar conditions (PR, 0.57; [95% confidence interval, .44–.72]).

Conclusions

Despite US clinical guidelines, we observed low rates of outpatient treatment for COVID-19 among pregnant patients, indicating possible missed opportunities to treat COVID-19 illness during pregnancy and lactation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentPregnancy Complications, InfectiousCOVID-19HumansFemalePregnancyAdultUnited StatesYoung AdultOutpatientsAdolescentMiddle AgedSARS-CoV-2Cohort Studies

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviral medicationpregnancytreatment

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena California, USA.
  • Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles California, USA.
  • Practical Causal Inference Lab, UCLA, Los Angeles, California, USA.
  • School of Nursing and Health Professions, University of San Francisco, San Francisco California, USA.
  • School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne VIC, Australia.

ORCID-Profile: Annette K Regan, Stacey L Rowe, Matthew M Coates, Onyebuchi A Arah

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • NICHD NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Regan, A. K., Rowe, S. L., Sullivan, S. G., Coates, M. M., Muñoz, F. M., & Arah, O. A. (2025). COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients. Clinical Infectious Diseases, 80(3), 512-519. https://doi.org/10.1093/cid/ciae580

Vancouver

Regan AK, Rowe SL, Sullivan SG, Coates MM, Muñoz FM, Arah OA. COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients. Clinical Infectious Diseases. 2025;80(3):512-519. doi:10.1093/cid/ciae580

BibTeX
@article{Regan2025,
  author = {Regan, Annette K and Rowe, Stacey L and Sullivan, Sheena G and Coates, Matthew M and Muñoz, Flor M and Arah, Onyebuchi A},
  title = {COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {3},
  pages = {512--519},
  doi = {10.1093/cid/ciae580}
}
Kostenlos starten →